Pioneering digital solutions, for people with diabetes taking insulin, are to be brought to market as two top companies have announced a major collaboration.
Medtronic, the world’s largest medical device company, headquartered in Dubli, Ireland, has teamed up with Danish pharmaceutical giant Novo Nordisk and together they have pledged to make diabetes management easier by integrating key health technologies.
The partnership intends to develop solutions which will combine insulin dosing data from future Novo Nordisk smart insulin pens into Medtronic’s Continuous Glucose Monitoring (CGM) devices, such as the Guardian™ Connect system.
This new approach will mean healthcare professionals, caregivers and people with diabetes can automatically track blood glucose levels and insulin dosing, making the whole process a lot easier for all those involved, particularly for people with the condition.
It is hoped that these developments will save time for people with diabetes every day, as well as increasing the amount of time they spend within the normal blood glucose range.
Camilla Sylvest, executive vice president of Commercial Strategy & Corporate Affairs at Novo Nordisk, said: “Millions of people living with diabetes work to control their sugar levels and track their insulin injections every day. To help ease the hassle of diabetes management, we are excited to be partnering with Medtronic, the largest medical device company in the world.
“We now collaborate with all major CGM device producers, which means we can bring the benefits of smart insulin pens to even more people.”
Alejandro Galindo, president of the Advanced Insulin Management division within the Diabetes Group at Medtronic, added: “We see incredible power in combining a variety of data points to drive insights that help people living with diabetes make more informed decisions around managing their glucose levels.
“Our new agreement with Novo Nordisk, the world’s largest producer of insulin, will streamline the sharing of two of the most important pieces of information – glucose measurements and insulin dosed. With this, Medtronic can further enhance our market-leading analytics and insights to help ease the burden of diabetes.”
